Kestra Medical CEO sells 15,000 shares under plan

Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026.

Rhea-AI Filing Summary

Kestra Medical Technologies president, chief executive officer and director Brian Daniel Webster reported selling 15,000 common shares of KMTS on January 15, 2026. The sale was coded as an open-market sale and was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 29, 2025, indicating it was scheduled in advance. The shares were sold at a weighted average price of $22.8016, with individual sale prices ranging from $22.2800 to $23.1340. After this transaction, Webster beneficially owns 394,786 common shares, held directly.

Insider Trade Summary

Net Seller: 15,000 shares

Net Sell 1 txn

Insider Webster Brian Daniel

Role See Remarks

Sold 15,000 shs ($342K)

Type	Security	Shares	Price	Value
Sale	Common Shares	15,000	$22.8016	$342K

Holdings After Transaction: Common Shares — 394,786 shares (Direct)

Footnotes (2)

1. F1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
2. F2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2800 to $23.1340. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KMTS report for Brian Daniel Webster?

Brian Daniel Webster, president, chief executive officer and director of Kestra Medical Technologies, Ltd. (KMTS), reported an open-market sale of 15,000 common shares on January 15, 2026.

At what price were the KMTS shares sold in Brian Daniel Webster's Form 4?

The 15,000 KMTS common shares were sold at a weighted average price of $22.8016, with individual prices ranging from $22.2800 to $23.1340.

How many KMTS shares does Brian Daniel Webster own after the reported sale?

Following the reported transaction, Brian Daniel Webster beneficially owns 394,786 KMTS common shares, held directly.

Was the KMTS insider sale by Brian Daniel Webster under a Rule 10b5-1 plan?

Yes. The filing states that the transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

What role does Brian Daniel Webster hold at Kestra Medical Technologies (KMTS)?

Brian Daniel Webster is identified as a director and an officer, with the remarks specifying that he is the President and Chief Executive Officer of Kestra Medical Technologies, Ltd.

Is the reported KMTS Form 4 transaction direct or indirect ownership?

The Form 4 identifies the ownership form as direct (D), meaning the 394,786 shares after the sale are held directly by Brian Daniel Webster.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/20/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Webster Brian Daniel

(Last) (First) (Middle)

C/O KESTRA MEDICAL TECHNOLOGIES, LTD.

3933 LAKE WASHINGTON BLVD NE, SUITE 200

(Street)

KIRKLAND WA 98033

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KESTRA MEDICAL TECHNOLOGIES, LTD. [ KMTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	01/15/2026		S(1)		15,000	D	$22.8016(2)	394,786	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

2. The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2800 to $23.1340. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Remarks:

President and Chief Executive Officer

	/s/ Brian Daniel Webster	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.